May. 7 at 2:17 PM
Jefferies⬆️the PT on
$CYTK to
$105, reiterated at Buy, and said: CYTK hit on both dual primary endpoints in ACACIA-HCM.
$EWTX $BMY
SNY NVS AZN LLY JNJ AMGN MRK
Jefferies added—We think data came closer to our bull case HERE given:
1) both KCCQ & pVO2 were stat. sig. (we see larger effect size & lower pt variability vs ODYSSEY),
2) KCCQ improved out to wk72,
3) trial hit on key secondary endpoints, incl NYHA improvement (w/ data getting better over time in OLE) & NT-proBNP,
4) LVEF <50% looks better vs mava in nHCM (10% vs ~22%).
We raise our PS to
$1.5 in nHCM (PT
$90->
$105).
